GB947912A - Braxy and/or blackleg and/or black disease vaccines - Google Patents

Braxy and/or blackleg and/or black disease vaccines

Info

Publication number
GB947912A
GB947912A GB861959A GB861959A GB947912A GB 947912 A GB947912 A GB 947912A GB 861959 A GB861959 A GB 861959A GB 861959 A GB861959 A GB 861959A GB 947912 A GB947912 A GB 947912A
Authority
GB
United Kingdom
Prior art keywords
cells
vaccine
medium
toxin
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB861959A
Inventor
James Russell Hepple
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB861959A priority Critical patent/GB947912A/en
Publication of GB947912A publication Critical patent/GB947912A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C06—EXPLOSIVES; MATCHES
    • C06B—EXPLOSIVES OR THERMIC COMPOSITIONS; MANUFACTURE THEREOF; USE OF SINGLE SUBSTANCES AS EXPLOSIVES
    • C06B45/00—Compositions or products which are defined by structure or arrangement of component of product
    • C06B45/04—Compositions or products which are defined by structure or arrangement of component of product comprising solid particles dispersed in solid solution or matrix not used for explosives where the matrix consists essentially of nitrated carbohydrates or a low molecular organic explosive
    • C06B45/06—Compositions or products which are defined by structure or arrangement of component of product comprising solid particles dispersed in solid solution or matrix not used for explosives where the matrix consists essentially of nitrated carbohydrates or a low molecular organic explosive the solid solution or matrix containing an organic component
    • C06B45/10—Compositions or products which are defined by structure or arrangement of component of product comprising solid particles dispersed in solid solution or matrix not used for explosives where the matrix consists essentially of nitrated carbohydrates or a low molecular organic explosive the solid solution or matrix containing an organic component the organic component containing a resin
    • C06B45/105—The resin being a polymer bearing energetic groups or containing a soluble organic explosive
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/166—Catalysts not provided for in the groups C08G18/18 - C08G18/26
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/08—Processes
    • C08G18/16—Catalysts
    • C08G18/22—Catalysts containing metal compounds
    • C08G18/222—Catalysts containing metal compounds metal compounds not provided for in groups C08G18/225 - C08G18/26
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/30—Low-molecular-weight compounds
    • C08G18/38—Low-molecular-weight compounds having heteroatoms other than oxygen
    • C08G18/3819—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen
    • C08G18/3823—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing -N-C=O groups
    • C08G18/3825—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing -N-C=O groups containing amide groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/30—Low-molecular-weight compounds
    • C08G18/38—Low-molecular-weight compounds having heteroatoms other than oxygen
    • C08G18/3819—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen
    • C08G18/384—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing nitro groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/77—Polyisocyanates or polyisothiocyanates having heteroatoms in addition to the isocyanate or isothiocyanate nitrogen and oxygen or sulfur
    • C08G18/78—Nitrogen
    • C08G18/7868—Nitrogen containing nitro groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/83—Chemically modified polymers
    • C08G18/833—Chemically modified polymers by nitrogen containing compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A vaccine active against at least one of the following, namely Braxy in sheep, Black disease and Blackleg in sheep or cattle comprises an aqueous preparation including at least one of the following namely (A) at least 2.5 total combining units per ml. of preparation of toxoided toxin from a toxigenic strain of Clostridium septicum; (B) at least 5.0 flocculation equivalents per ml. of preparation of toxoided a -toxin from a toxigenic strain of Clostridium oedematiens type B and (C) at least 106 per ml. of preparation of killed cells of a toxigenic strain of Clostridium chauvoei, which cells may be partially or wholly replaced by an extract thereof, the preparation containing p not more than 1.0 mg. total nitrogen or 1.0 mg. protein nitrogen per individual antigenic component of the vaccine. The vaccine is prepared by culturing separately a toxigenic strain of Cl. chauvoei, Cl. septicum or Cl. oedematiens type B in a culture medium therefor; separating the cells from the culture medium; where required, toxoiding the toxin in the medium and ultrafiltering the medium to remove some of the water and medium ingredients; where required, killing the separated cells and, where required, extracting the whole or part of said cells; followed, where required, by blending the products so obtained to form a vaccine as above. The blackleg vaccine is obtained by cultivating Cl. chauvoei in a nutrient medium containing enzymatic digest of meat at pH 7.6 to 7.8 at 37 DEG C. under anaerobic conditions for 48 hours. After centrifugation, the cells are killed by formalinisation (1%) for 7-10 days until sterile. The medium is filtered and treated with 1% formalin at pH 7.4 and 37 DEG C. for 5 to 6 days to form toxoid. It is purified by (a) ultrafiltration through a collodion or cellulose membrane until the volume of the medium is reduced 50 times; (b) dialysis of the concentrated toxoided toxin against sodium acetate/acetic acid solution for 2 to 3 days and redissolving the precipitate so formed in a phosphate buffer at pH 6.5. Both killed cells and the purified toxoided toxin may be separately absorbed on to a parenterally acceptable absorbent such as aluminium hydroxide gel and then mixed together to form a vaccine which may also contain isotonic sodium chloride and a preservative. The braxy vaccine consists of a toxoid and lysate of cells of Cl. septicum. The lysate being prepared by treating the cells with strong saline and dialysing to remove inorganic salts. Braxy, Blackleg and Black Disease vaccines may be mixed, either singly or in combination, with preparations active against tetanus and/or Pulpy Kidney Disease in lambs. Specification 901,433 is referred to.
GB861959A 1959-03-12 1959-03-12 Braxy and/or blackleg and/or black disease vaccines Expired GB947912A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB861959A GB947912A (en) 1959-03-12 1959-03-12 Braxy and/or blackleg and/or black disease vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB861959A GB947912A (en) 1959-03-12 1959-03-12 Braxy and/or blackleg and/or black disease vaccines

Publications (1)

Publication Number Publication Date
GB947912A true GB947912A (en) 1964-01-29

Family

ID=9855963

Family Applications (1)

Application Number Title Priority Date Filing Date
GB861959A Expired GB947912A (en) 1959-03-12 1959-03-12 Braxy and/or blackleg and/or black disease vaccines

Country Status (1)

Country Link
GB (1) GB947912A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264588A (en) * 1979-05-10 1981-04-28 The Charles River Breeding Laboratories, Inc. Vaccine for Clostridium perfringens type E enterotoxemia of rabbits
US4292307A (en) * 1977-09-30 1981-09-29 Zemlyakova Valentina P Vaccine and method for prophylaxis and treatment of clostridioses of animals and poultry

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292307A (en) * 1977-09-30 1981-09-29 Zemlyakova Valentina P Vaccine and method for prophylaxis and treatment of clostridioses of animals and poultry
US4264588A (en) * 1979-05-10 1981-04-28 The Charles River Breeding Laboratories, Inc. Vaccine for Clostridium perfringens type E enterotoxemia of rabbits

Similar Documents

Publication Publication Date Title
MacLennan The histotoxic clostridial infections of man
Barnes The enzymes of lymphocytes and polymorphonuclear leucocytes
Bosworth On a new type of toxin produced by Clostridium welchii
JP4129544B2 (en) Multi-component clostridial vaccine using saponin adjuvant
Dubos et al. The effect of a tissue enzyme upon pneumococci
CN106177935A (en) A kind of ruminant clostridial disease tetrad inactivated vaccine and preparation method thereof
Kameyama et al. Purification and some properties of kappa toxin of Clostridium perfringens
Hauschild Clostridiumperfringens toxins types B, C, D and E
GB947912A (en) Braxy and/or blackleg and/or black disease vaccines
JPS6211090A (en) Toreponema hyodicenteriae bacterin and its method
CN105169380A (en) Bivalent propolis inactivated vaccine for rabbit hemorrhagic disease and multocida pasteurellosis and preparation method of bivalent propolis inactivated vaccine
SU997599A3 (en) Process for preparing heterovaccine for treating trichomonas syndrome
Ellner Fate of partially purified C14-labeled toxin of Clostridium perfringens
McEwen B. paludis: A new species of pathogenic anaerobic bacterium
Tidwell et al. Use of membrane filter in blood cultures.
GB2023420A (en) Preparations containing antigen from pasteurella haemolytica
Auclair et al. Formic acid as a growth stimulant for Lactobacillus lactis in autoclaved milk
Fisher Experimental Staphylococcal Infection of the Subcutaneous Tissue of the Mouse: II. Promotion of the Infection with Staphylococcal Cells and Products
CN104000851A (en) Snake venom extract capable of replacing antibiotic and preparation method and application thereof
US3288680A (en) Stabilized clostridium perfringens beta-toxoid vaccine
CN111467488B (en) Water-soluble composite immunoadjuvant and application thereof
Keppie et al. The Chemical Basis of the Virulence of Pasteurella pestis: III. An Immunogenic Product Obtained from Past. pestis which Protects both Guinea-pigs and Mice
RU2109519C1 (en) Method of preparing vaccine for necrobacteriosis control in animals
Springer et al. Protection of mice against lethal Staphylococcus infection by Escherichia coli O86 fractions
CN113559256B (en) Nocardia immunopotentiator and application thereof in preparation of pig vaccine